Status:
COMPLETED
Different Approaches for the Management of Post-dural Puncture Headache
Lead Sponsor:
Bahaa Mohammed Refaie
Conditions:
Post-Dural Puncture Headache
Eligibility:
FEMALE
20-45 years
Phase:
NA
Brief Summary
Detecting the efficacy and safety of trans-nasal sphenopalatine ganglion block using either lidocaine 2% or bupivacaine 0.5 % as a treatment line for post-dural puncture headache
Eligibility Criteria
Inclusion
- The ASA physical condition І-П
- the patient underwent CS under spinal anesthesia
- The headache developed within 5 days after the dural puncture
- There is no different explanation for the headache
Exclusion
- coagulopathy
- history of nasal bleeding
- nasal polyp
- septal deviation
- local anesthetics reaction
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05253014
Start Date
January 1 2018
End Date
December 30 2020
Last Update
February 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag faculty of medicine
Sohag, Egypt, 82524